Related Experiment Video
Updated: Jul 14, 2025
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans
Taymeyah Al-Toubah1, Jaime Montilla-Soler2, Ghassan El-Haddad2
1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; and.
Abstract:
Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine tumors (NETs) has not been well characterized using PET imaging. Understanding the degree and uniformity of SSTR expression is important to establish the role of SSTR-targeted treatments in lung NETs. Methods: A retrospective institutional review of patients with metastatic lung NETs who underwent DOTATATE PET imaging from March 2017 to February 2023 was performed. Results: In total, 48 patients with metastatic lung NETs who underwent 68Ga- or 64Cu-DOTATATE PET imaging were identified. Four had completely negative SSTR expression, and 10 had very weak expression (less than in a normal liver). Among the remaining 34 patients, 21 had uniformly positive DOTATATE PET scans, and 13 had heterogeneous expression. Only 44% had uniformly positive receptor expression, identifying them as candidates for peptide receptor radionuclide therapy. Conclusion: Most metastatic lung NETs lack uniform SSTR expression and are thus suboptimal candidates for SSTR-targeted therapy. SSTR imaging in lung NETs should be evaluated carefully for uniformity of expression.
Insights
Most metastatic lung neuroendocrine tumors (NETs) show non-uniform somatostatin receptor (SSTR) expression on DOTATATE PET scans. This heterogeneity makes them less suitable for SSTR-targeted therapies like peptide receptor radionuclide therapy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine tumors (NETs) requires better characterization.
- Understanding SSTR expression is crucial for evaluating SSTR-targeted treatments in lung NETs.
Purpose of the Study:
- To characterize the degree and uniformity of SSTR expression in metastatic lung NETs using DOTATATE PET imaging.
- To determine the proportion of lung NET patients suitable for SSTR-targeted therapy based on imaging findings.
Main Methods:
- Retrospective review of 48 patients with metastatic lung NETs who underwent 68Ga- or 64Cu-DOTATATE PET imaging.
- Analysis of DOTATATE PET scans to assess SSTR expression levels (negative, weak, uniform, heterogeneous).
Main Results:
- Four patients (8%) had negative SSTR expression, and 10 (21%) had very weak expression.
- Of the remaining 34 patients, 21 (44% of total) showed uniformly positive SSTR expression, while 13 (27% of total) had heterogeneous expression.
- Only 44% of patients had uniformly positive receptor expression, indicating suitability for peptide receptor radionuclide therapy.
Conclusions:
- Most metastatic lung NETs exhibit heterogeneous or insufficient SSTR expression.
- Uniform SSTR expression is uncommon in metastatic lung NETs, limiting their candidacy for SSTR-targeted therapies.
- Careful evaluation of SSTR expression uniformity is essential for guiding treatment decisions in lung NET patients.
More Related Videos
Related Concept Videos
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...